E
Edie Weller
Researcher at Harvard University
Publications - 121
Citations - 13723
Edie Weller is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 47, co-authored 118 publications receiving 12436 citations. Previous affiliations of Edie Weller include Celgene & Stanford University.
Papers
More filters
Journal ArticleDOI
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
Thomas M. Habermann,Edie Weller,Vicki A. Morrison,Randy D. Gascoyne,Peter A. Cassileth,Jeffrey B. Cohn,Shaker R. Dakhil,Bruce A. Woda,Richard I. Fisher,Bruce A. Peterson,Sandra J. Horning +10 more
TL;DR: Rituximab administered as induction or maintenance with CHOP chemotherapy significantly prolonged FFS in older DLBCL patients, which are consistent with an additive effect of ritUXimab.
Journal ArticleDOI
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Edie Weller,Edie Weller,Teru Hideshima,Teru Hideshima,Constantine S. Mitsiades,Constantine S. Mitsiades,Faith E. Davies,Faith E. Davies,Richard Leblanc,Richard Leblanc,Laurence Catley,Laurence Catley,Deborah Doss,Deborah Doss,Kathleen Kelly,Kathleen Kelly,Mary McKenney,Mary McKenney,Julie Mechlowicz,Julie Mechlowicz,Andrea Freeman,Andrea Freeman,Reggie Deocampo,Reggie Deocampo,Rebecca Rich,Rebecca Rich,Joan J. Ryoo,Joan J. Ryoo,Dharminder Chauhan,Dharminder Chauhan,Kathe Balinski,Kathe Balinski,Jerome B. Zeldis,Jerome B. Zeldis,Kenneth C. Anderson,Kenneth C. Anderson +38 more
TL;DR: This study provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease and shows no significant somnolence, constipation, or neuropathy has been seen in any cohort.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal,Valérie Lauwers-Cances,Cyrille Hulin,Xavier Leleu,Denis Caillot,Martine Escoffre,Bertrand Arnulf,Margaret Macro,Karim Belhadj,Laurent Garderet,Murielle Roussel,Catherine Payen,Claire Mathiot,Jean Paul Fermand,Nathalie Meuleman,Sandrine Rollet,Michelle E. Maglio,Andrea A. Zeytoonjian,Edie Weller,Nikhil C. Munshi,Kenneth C. Anderson,Paul G. Richardson,Thierry Facon,Hervé Avet-Loiseau,Jean-Luc Harousseau,Philippe Moreau +25 more
TL;DR: Among adults with multiple myeloma, RVD therapy plus transplantation was associated with significantly longer progression‐free survival than RVD Therapy alone, but overall survival did not differ significantly between the two approaches.
Journal ArticleDOI
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G. Richardson,Edie Weller,Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Noopur Raje,David Avigan,Wanling Xie,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Robin Joyce,Jonathan L. Kaufman,Deborah Doss,Diane Warren,Laura E. Lunde,Sarah Kaster,Carol Delaney,Teru Hideshima,Constantine S. Mitsiades,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +24 more
TL;DR: Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma.
Journal ArticleDOI
BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro,Antonio Sacco,Patricia Maiso,Abdel Kareem Azab,Yu-Tzu Tai,Michaela R. Reagan,Feda Azab,Ludmila Flores,Federico Campigotto,Edie Weller,Kenneth C. Anderson,David T. Scadden,Irene M. Ghobrial +12 more
TL;DR: In vitro and in vivo studies demonstrated that exosome transfer from BM-MSCs to clonal plasma cells represents a previously undescribed and unique mechanism that highlights the contribution of BM- MSCs to MM disease progression.